These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

873 related articles for article (PubMed ID: 25957392)

  • 21. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts.
    Chen Z; Wang SA; Goswami M; Tang G; Routbort MJ; Patel KP; Luthra R; Medeiros LJ; Ok CY
    Leuk Res; 2019 Nov; 86():106227. PubMed ID: 31557598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.
    Migdady Y; Barnard J; Al Ali N; Steensma DP; DeZern A; Roboz G; Garcia-Manero G; Sekeres MA; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):528-532. PubMed ID: 29937400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis.
    Broséus J; Alpermann T; Wulfert M; Florensa Brichs L; Jeromin S; Lippert E; Rozman M; Lifermann F; Grossmann V; Haferlach T; Germing U; Luño E; Girodon F; Schnittger S;
    Leukemia; 2013 Sep; 27(9):1826-31. PubMed ID: 23594705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.
    Dolatshad H; Pellagatti A; Fernandez-Mercado M; Yip BH; Malcovati L; Attwood M; Przychodzen B; Sahgal N; Kanapin AA; Lockstone H; Scifo L; Vandenberghe P; Papaemmanuil E; Smith CW; Campbell PJ; Ogawa S; Maciejewski JP; Cazzola M; Savage KI; Boultwood J
    Leukemia; 2015 May; 29(5):1092-103. PubMed ID: 25428262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis with Cooccurrent SF3B1 and MPL Gene Mutations: A Case Report and Brief Review of the Literature.
    Park CH; Yun JW; Kim HY; Lee KO; Kim SH; Kim HJ
    Lab Med; 2020 May; 51(3):315-319. PubMed ID: 31858134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
    Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
    BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
    Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
    Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype.
    Visconte V; Tabarroki A; Rogers HJ; Hasrouni E; Traina F; Makishima H; Hamilton BK; Liu Y; O'Keefe C; Lichtin A; Horwitz L; Sekeres MA; Hsieh FH; Tiu RV
    Haematologica; 2013 Sep; 98(9):e105-7. PubMed ID: 23831919
    [No Abstract]   [Full Text] [Related]  

  • 29. Splicing factor mutations in MDS RARS and MDS/MPN-RS-T.
    Yoshimi A; Abdel-Wahab O
    Int J Hematol; 2017 Jun; 105(6):720-731. PubMed ID: 28466384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or
    Mortuza S; Chin-Yee B; James TE; Chin-Yee IH; Hedley BD; Ho JM; Saini L; Lazo-Langner A; Schenkel L; Bhai P; Sadikovic B; Keow J; Sangle N; Hsia CC
    Curr Oncol; 2024 Mar; 31(4):1762-1773. PubMed ID: 38668037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts.
    Visconte V; Tabarroki A; Zhang L; Parker Y; Hasrouni E; Mahfouz R; Isono K; Koseki H; Sekeres MA; Saunthararajah Y; Barnard J; Lindner D; Rogers HJ; Tiu RV
    J Hematol Oncol; 2014 Dec; 7():89. PubMed ID: 25481243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Features and clinical significance of gene mutations in patients with myelodysplastic syndromes with ring sideroblasts].
    Cai YN; Xu ZF; Li B; Qin TJ; Pan LJ; Qu SQ; Hu NB; Liu D; Huang HJ; Shi ZX; Zhang YD; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):379-386. PubMed ID: 32536134
    [No Abstract]   [Full Text] [Related]  

  • 33. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.
    Malcovati L; Stevenson K; Papaemmanuil E; Neuberg D; Bejar R; Boultwood J; Bowen DT; Campbell PJ; Ebert BL; Fenaux P; Haferlach T; Heuser M; Jansen JH; Komrokji RS; Maciejewski JP; Walter MJ; Fontenay M; Garcia-Manero G; Graubert TA; Karsan A; Meggendorfer M; Pellagatti A; Sallman DA; Savona MR; Sekeres MA; Steensma DP; Tauro S; Thol F; Vyas P; Van de Loosdrecht AA; Haase D; Tüchler H; Greenberg PL; Ogawa S; Hellstrom-Lindberg E; Cazzola M
    Blood; 2020 Jul; 136(2):157-170. PubMed ID: 32347921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a high-resolution melting analysis for the detection of the SF3B1 mutations.
    Yang J; Qian J; Lin J; Yang XF; Qian W; Chen Q; Yao DM; Wang CZ; Chen XX; Xiao GF; Ma YJ
    Genet Test Mol Biomarkers; 2013 Apr; 17(4):342-7. PubMed ID: 23390883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes.
    Patel JL; Abedi M; Cogle CR; Erba HP; Foucar K; Garcia-Manero G; Grinblatt DL; Komrokji RS; Kurtin SE; Maciejewski JP; Pollyea DA; Revicki DA; Roboz GJ; Savona MR; Scott BL; Sekeres MA; Steensma DP; Thompson MA; Dawn Flick E; Kiselev P; Louis CU; Nifenecker M; Swern AS; George TI
    Int J Lab Hematol; 2021 Jun; 43(3):426-432. PubMed ID: 33220019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts.
    Janusz K; Del Rey M; Abáigar M; Collado R; Ivars D; Hernández-Sánchez M; Valiente A; Robledo C; Benito R; Díez-Campelo M; Ramos F; Kohlmann A; Cañizo CD; Hernández-Rivas JM
    Leuk Res; 2017 May; 56():82-87. PubMed ID: 28222336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS).
    Martín I; Such E; Navarro B; Vicente A; López-Pavía M; Ibáñez M; Tormo M; Villamón E; Gómez-Seguí I; Luna I; Oltra S; Pedrola L; Sanz MA; Cervera J; Sanz G
    Leuk Lymphoma; 2017 Jul; 58(7):1686-1693. PubMed ID: 27771989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.
    Tang Y; Miao M; Han S; Qi J; Wang H; Ruan C; Wu D; Han Y
    Crit Rev Oncol Hematol; 2019 Jan; 133():74-83. PubMed ID: 30661660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".
    Patnaik MM; Tefferi A
    Am J Hematol; 2019 Apr; 94(4):475-488. PubMed ID: 30618061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts.
    Visconte V; Makishima H; Jankowska A; Szpurka H; Traina F; Jerez A; O'Keefe C; Rogers HJ; Sekeres MA; Maciejewski JP; Tiu RV
    Leukemia; 2012 Mar; 26(3):542-5. PubMed ID: 21886174
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.